Stocks Thrive on Tariff Relief
Stocks rose Tuesday after President Donald Trump said over the holiday weekend that he agreed to delay tariffs of 50% on the European Union.The Dow Jones Industrials sprang 473.18 points, or 1.1%, to 42,076.75.The S&P 500 revived 87.45 points, or 1.5%, to 5,890.82The NASDAQ Composite popped 367.48 points, or 2%, to 19,104.69. Trump on Sunday said that he would push back the 50% levy deadline on the EU to July 9 following a request from Ursula von der Leyen, the president of the European Commission. That comes after Trump last week proposed an import tax of 50% on the EU beginning June 1.Tesla shares popped 4% after CEO Elon Musk said he was shifting his focus away from politics and back into his companies. Other tech-related names were also higher, including Nvidia, AMD, Apple and Microsoft. Traders this week will follow earnings from Okta due after the bell Tuesday, followed by companies such as Nvidia, Macy’s and Costco later in the week. More than 95% of S&P 500 companies have reported this earnings season and almost 78% have surpassed analyst expectations.Prices for the 10-year Treasury were higher to open a short week Tuesday, lowering yields to 4.46% from Friday’s 4.51%. Treasury prices and yields move in opposite directions. Oil prices retreated 56 cents to $60.97 U.S. a barrel. Prices for gold fell $71.00 to $3,294.800.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


